Previous studies indicate that exposure of fibrinogen receptors associated with glycoprotein lIb/llla complex contributes to platelet loss during cardiopulmonary bypass. Recently, we isolated a number of RGD (Arg-Gly-Asp)-containing, low molecular weight, cysteine-rich peptides from viper venoms. These peptides, which we propose to call "disintegrins," block platelet-fibrinogen interaction and platelet aggregation. We compared the effect of RGDS (Arg-Gly-Asp-Ser) and four disintegrins (echistatin, flavoridin, albolabrin, and bitistatin) on platelet behavior in a membrane oxygenator. During simulated extracorporeal circulation for 2 hours, platelet count decreased to about 30% of initial values. Addition of echistatin (60-200 nM), albolabrin (60-200 nM), bitistatin (60 nM), and flavoridin (45 nM) significantly inhibited platelet loss in the circuit. RGDS (33 /lM) did not show any significant inhibitory effect. ADP-induced platelet aggregation was inhibited in samples of platelet-rich plasma taken from the circuits containing disintegrins. However, echistatin appeared to be a more potent inhibitor of platelet aggregation, whereas albolabrin and flavoridin interfered more selectively with platelet loss from the circuit. Echistatin prevented the accumulation of glycoprotein IlIa on the surface of the circuit. Echistatin (60-200 nM), flavoridin (45 nM), bitistatin (60 nM), and albolabrin (200 nM) significantly inhibited the loss of j-thromboglobulin from platelets into circulating plasma. Electron microscopy studies demonstrated shape change but not degranulation in platelets circulating in the presence of 200 nM echistatin. On the other hand, this peptide (up to 1,000 nM) did not prevent loss of a granules and ,3-thromboglobulin from thrombin-stimulated platelets, although it prevented their aggregation. In conclusion, disintegrins protect platelets in the circuit by preventing their adhesion to surfaces and, therefore, preventing fragmentation of adhered platelets under the shear stress of flowing blood. This study indicates that distintegrins may be potential candidates for platelet protection during cardiopulmonary bypass. (Circulation 1990;82:261-273) Cardiopulmonary bypass involves extensive contact between blood and synthetic surfaces of the membrane oxygenator. Bypass produces thrombocytopenia,1"2 platelet fragmen-
ANTI-CYTOADHESIVE PEPTIDES FROM SNAKE VENOMS (DISINTEGRINS)
VSPPVCGNKILEQ--GEDCDCGSPANCQDQCCNAATCKLTPGSQCNHGECCDQCKFKKARTVCRIARGDWNDDYCTGKSSDCPWNH FIGURE 1 . Amino acid sequences of anticytoadhesive peptides from snake venoms (disinteg,ins). Albolabrin was prepared from
Trimeresurus albolabris, flavondin from T. flavoviridis, echistatin from Echis carinatus, and bitistatin from Bitis arietans.
gen molecule: RGDS (Arg-Gly-Asp-Ser),'3 RGDF (Arg-Gly-Asp-Phe),14 and tyrosyl pentadecapeptide of the C-terminal portion of the y chain. 15 The concentrations of these peptides required for inhibition of platelet aggregation range from 10 to 200 gM.
Recently, three RGD-containing, cysteine-rich peptides (trigramin,1617 echistatin,18 and bitistatinl9) were isolated from Trimresurus gramineus, Echis carinatus, and Bitis arietans snake venoms, respectively. On a molar basis, trigr,min (Mr, 7,500 d), echistatin (Mr, 5,400 d), and bitistatin (Mr, 9,022 d) are about 500-2,000 times more potent in blocking platelet-fibrinogen interaction and fibrinogen-dependent platelet aggregation than is RGDS. Several similar peptides showing a high degree of amino acid sequence homology with trigramin and echistatin have been isolated from other viper venoms.20-22 These peptides represent a new class of proteins that we propose to call "disintegrins,"20 because they interfere with the interaction of adhesive ligands with their integrin receptors. The name of each disintegrin is derived from the name of the species or subspecies of the viper. Disintegrins appear to be nontoxc, but they interfere with the formation of platelet hemostatic plugs and platelet thromboemboli formation in vivo.1923
The purpose of this study was to evaluate the effect of RGDS and four disintegrins (echistatin, albolabrin, flavoridin, and bitistatin) on platelet behavior during simulated extracorporeal circulation.
Methods Reagents ADP, aprotinin, prostaglandin El (PGE1), benzamidine, EDTA, E-amino-n-caproic acid (EACA), soybean trypsin inhibitor (SBTI), and Triton X-100 were obtained from Sigma Chemical Co., St Group, Hesperia, Calif.]). The gradient used was 0.1% trifluoroacetic acid containing 0-40% acetonitrile. A single active peak was identified by screening for inhibition of ADP-induced platelet aggregation. This peak was lyophilized and repurified on an identical C-18 column with a more gentle gradient. Both albolabrin and flavoridin showed only one NH2-terminal sequence. NH2-terminal sequencing of the reduced and pyridylethylated disintegrins and peptides obtained by their proteolytic degradation was performed on a gas-phase sequencer (model 120A, Applied Biosystems, Inc.) coupled to an online PTH analyzer (model 120A, Applied Biosystems Inc.). As seen in Figure 1 , three of the disintegrins showed a high degree of homology, particularly with respect to the alignment of RGD and cysteines. Albolabrin had only eight amino acid changes from the previously characterized trigramin.17 Albolabrin, flavoridin, and echistatin are composed of 73, 71, and 49 amino acids, respectively ( Figure 1 In control experiments, 300 ml human blood was drawn directly into a reservoir bag containing beef lung heparin (5 units/ml blood) and glucose (3.3 mg/ml blood). In addition, in each experimental study, the reservoir bag contained echistatin (20, The perfusion system was filled with blood without air formation, and the reservoir bag was immersed in a constant temperature water bath at 370 C. Blood (250 ml) was recirculated by a precisely shimmed, barely occlusive roller pump at a rate of 0.3 1/min for 120 minutes. This rate of flow was slower than in the previous studies6"1 and thus would result in a less extensive loss of platelets from the circulation compared with previous experiments.6 '1 The oxygenator was ventilated with 95% 02-5% CO2 at a rate of 0.7 1/min.
After 120 minutes, blood was drained from the entire system and replaced with two consecutive wash solutions (250 ml each): 1) 0.9% saline and 2) 0.5% Triton X-100. Both solutions contained 0.01 M EDTA, 0.3 M EACA, 500 gg/ml SBTI, and 0.001 M benzamidine. Each solution was recirculated for 15 minutes.
Sampling Procedure
Blood samples were taken directly from the donor's vein and from the reservoir bag before connection to the circuit. An initial control sample was processed immediately, and a second sample, the standing control, was processed after 120 minutes in a water bath at 370 C. Samples were obtained from the circuit at 5, 30, 60, and 120 minutes of recirculation. Additional samples of saline and Triton X-100 rinse were taken at the end of each respective 15-minute recirculation. Blood was collected after mixture with each of the following: 1) 0.11 M sodium citrate (9:1, vol/vol), 2) EDTA-PGE, mixture (9:1, voll/vol),2 and 3) citric acid-sodium citrate-dextrose (ACD, 9: 1, vol/vol). Platelet-rich plasma and platelet-poor plasma were prepared from citrated blood by differential centrifugation as described previously."
Blood collected and mixed with ACD was centrifuged at 1,100g (20 
Platelet Studies
Platelet aggregation studies in platelet-rich and gelfiltered plasma were performed with an aggregometer (Chrono-Log, Havertown, Pa.). In platelet-rich plasma, threshold doses of ADP (i.e., the lowest dose of the agonist able to produce irreversible aggregation of at least 62% after 5 minutes) were determined. /3-Thromboglobulin Antigen 13-Thromboglobulin antigen was determined by means of a radioimmunoassay as previously described. 29 Samples taken from the reservoir bag for ,3-thromboglobulin radioimmunoassay were mixed with EDTA-PGE, solution.
Glycoprotein IIIa Antigen
Glycoprotein IIla antigen in the Triton X-100 eluates from the perfusion circuit was identified by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis30 followed by Western blotting31 with the methodology and reagents described previously.1
Electron Microscopy
Platelet-rich plasma from samples taken from the reservoir bag (with and without echistatin) after 120 minutes of recirculation were examined. Also, gelfiltered platelets treated with various ratios of thrombin and echistatin and stirred in aggregometer tubes for 3 minutes were examined. These samples were fixed with glutaraldehyde in Tyrode's solution containing 2% sucrose. Platelets were further fixed in 1% osmium tetraoxide, stained with uranyl acetate, dehydrated with a graded ethanol series, and embedded in plastic for sectioning and further staining (uranyl acetate and lead citrate).
Statistical Analysis
The effect of various peptides on the number of platelets remaining in the circulation (% of control) and 3-thromboglobulin levels at various times during recirculation were compared statistically with a twoway analysis of variance (ANOVA) (peptide by time). Because the ANOVA F tests demonstrated significant differences (acceptable a level, 0.05), Tukey's honestly significant difference posthoc analysis was performed to determine differences between simple main-effect means. The ratios representing inhibition of platelet loss to inhibition of platelet aggregation for echistatin (60 nM), bitistatin (60 nM), flavoridin (45 nM), and albolabrin (200 nM) were compared with a single factor analysis of variance. Figure 2 summarizes the effects of recirculation on platelet number with and without RGDS and disintegrins. The statistical analysis of the curves compared by ANOVA is presented in Table 1 . Without protective agents, the platelet count in circulating blood decreased significantly. The greatest decrease, to about 30% of initial values, occurred within 5-30 minutes. By 2 hours, the platelet count had increased but did not exceed 45%o of initial values. RGDS, at a concentration of 33,000 nM, appeared to have a slight protective effect that was not statistically significant. The protective effects of echistatin (60 nM), flavoridin (45 nM), and bitistatin (60 nM) were similar, whereas that of albolabrin (60 nM) was slightly less effective. Samples containing all four disintegrins were statistically different from control samples ( Table 2) ; samples containing flavoridin were also significantly different from albolabrin samples. In addition, we observed that the increase in concentration of echistatin from 60 to 200 nM resulted in the increase of mean platelet preservation from 85.1% to 96.8%, and the increase in concentration of albolabrin from 60 to 200 nM resulted in the increase of mean platelet preservation from 66.5% to 84.2% (data not shown).
Results

Prevention of Platelet Loss in the Simulated Extracorporeal Circuit by Disintegrins
To determine the correlation between the protective effect of disintegrins on circulating platelets and their inhibitory effect on ADP-induced aggregation, we tested platelet aggregation in response to ADP in platelet-rich plasma prepared from blood samples taken from the reservoir bag before recirculation. The inhibitory effect of disintegrins on platelet aggregation was expressed in percent inhibition compared with control samples. All aggregation was performed in platelet-rich plasma stimulated at identical (threshold) concentrations of ADP. Preservation of platelets was expressed as mean platelet count in samples taken from the reservoir bag at 5, 30, 60, and 120 minutes of recirculation; platelet count before recirculation was accepted as 100%. Table 1 shows the comparison of the effect of four disintegrins on preservation of circulating platelets and inhibition of platelet aggregation in platelet-rich plasma. The ratio of the percentage of preserved platelets and inhibition of platelet aggregation was calculated for each disintegrin. When the ratio is higher, the effect on platelet aggregation is smaller, and the effect on platelet preservation is greater. Table  1 shows that the selected concentrations of the four disintegrins in this comparative study (60 nM echistatin, 60 nM bitistatin, 45 nM flavoridin, and 200 nM albolabrin) provided similar protection of platelets in the circuit (80.2-89.2%). However, echistatin had a much stronger inhibitory effect on platelet aggregation than albolabrin and flavoridin. ANOVA (Table 1) confirmed that the dissociation of the effects on platelet aggregation and platelet preservation observed in this experiment was statistically significant.
Scanning electron microscopy was used to examine the appearance of platelets adhering to the circuit surface membrane. Amorphous materials, but no intact platelets, were found on the surface of the extracorporeal circuit. This material probably represented fragmented or degranulated platelets. Accumulation of glycoprotein IlIa antigen on the surface of the perfusion system, in extracts solubilized by Triton X-100, is shown in Figure 3 by means of SDS-polyacrylamide gel electrophoresis followed by Western blotting. In the absence of protective agents, the platelet count decreased from 224 to 71 x 103,ul during recirculation, and a high concentration of glycoprotein IlIa was present in the Triton X-100 extract ( Figure 3, during simulated extracorporeal circulation was also examined ( Figure 4 and Table 3 ). RGDS (30,000 nM) and albolabrin (60 nM) had no significant effect.
However, echistatin (60 nM), albolabrin (200 nM), flavoridin (45 nM), and bitistatin (60 nM) blocked the release of 13-thromboglobulin from platelets.
Although flavoridin (45 nM) appeared to be the most effective, a higher concentration of echistatin (200 nM) had similar effects (data not shown).
The ultrastructures of platelets circulated in the presence and absence of 200 nM echistatin were compared. Echistatin does not appear to prevent platelet shape change and pseudopod projection. Platelet a granules were preserved in samples with and without echistatin ( Figure 5 , panels A and B).
In an attempt to explain the protective effects of disintegrins on platelets during extracorporeal circulation, we studied the effects of echistatin on fil of the eluates were applied on sodium dodecyl sulfate-polyac,ylamide gels (with 7.5% gels), and electrophoretic sepafration was performed according to Laemmli.24 Samples were transferred to nitrocellulose papers and stained with an antibody to the 66-kd component derived from GPIIIa as described previously. ' As shown in panel D, control platelets showed a characteristic increase in light transmission; however, in the presence of echistatin, there was a limited increase in light transmission, but no large aggregates were formed as demonstrated by eye and by phase contrast microscopy. Groups of two or three platelets formed early during the light transmission increase, but their size and number did not continue to increase as light transmission increased. Release of 13-thromboglobulin antigen was close to 100% in the presence and in the absence of echistatin (data not shown).
Discussion
This study shows that the disintegrins echistatin, flavoridin, bitistatin, and albolabrin, which were prepared from snake venoms, prevent platelet adhesion to surfaces of simulated extracorporeal circuits. The activity of these peptides in this experimental system exhibited limited correlation with the ability of these peptides to inhibit platelet aggregation (Table 1) . That is, flavoridin and albolabrin appeared to be more selective inhibitors of platelet adhesion, whereas echistatin and bitistatin were more selective inhibitors of platelet aggregation. Because disintegrins block fibrinogen interaction with platelet receptors,16-21,25 the present data support the previously suggested contention that the interaction of the platelet glycoprotein lIb/llla complex with surface adsorbed fibrinogen is a major factor for platelet adhesion to these surfaces.1"
Disintegrins also blocked the loss of 3-thromboglobulin from platelets into circulating plasma (Figure 4) . Our data suggest that the release of platelet constituents into the circulation takes place on the surfaces of the circuit after platelets adhere. The most plausible explanation is that the shear stress of flowing blood contributes to the loss of platelet constituents. This conclusion is supported by the observation that most of the circulating platelets are not degranulated ( Figure 5 ) despite a significant increase of plasma 18-thromboglobulin. The results of this study and an earlier one from our laboratory'1 indicate that platelets that adhere undergo fragmentation. That is, although morphologically recognizable platelets are absent on the tubing, the glycoprotein IIla antigen is present in detergent washes of the perfusion circuit ( Figure 3) . Platelet fragmentation during cardiopulmonary bypass also has been observed by other researchers.4,5 Flavoridin appeared to be the most potent inhibitor of the release of ,B-thromboglobulin from platelets into the plasma.
Huang et al16 reported that trigramin inhibits platelet aggregation but that it does not inhibit release of serotonin induced by thrombin or a prostaglandin H2/thromboxane A2 analogue. Accordingly, we found that echistatin, an inhibitor of platelet aggregation induced by thrombin, did not block shape change and loss of ,3-thromboglobulin and a granules from platelets stimulated by this enzyme (Figure 6 ). We believe that disintegrins do not prevent the platelet release reaction that follows stimulation of specific surface receptors but that they do prevent platelet adhesion and, secondarily, the fragmentation that may occur under the shear stress of flowing blood.
Levy-Toledano et al32 reported that in response to the calcium ionophore A23187, thrombasthenic and EDTA-treated platelets undergo a change in light transmission accompanied by normal release of serotonin in the absence of aggregation. This ultrastructural change (vacuolization) was responsible, at least in part, for the increase of light transmission in the absence of platelet aggregates. The platelet ultrastructural changes reported by Levy-Toledano et al32 were similar to the changes in platelets induced by thrombin in the presence of echistatin and described in our present study ( Figure 6 ). Therefore, in our experiments, the platelet vacuolization in the presence of thrombin and echistatin could contribute to the increase of observed light transmission.
Of special interest, albolabrin and flavoridin, at concentrations that partially blocked ADP-induced platelet aggregation, provided relatively better protection of platelets in the circuit than did echistatin, which was a more potent inhibitor of platelet aggregation. This suggests that platelet adhesion to the membranes of the circuit and platelet adhesion to each other occur by different mechanisms. As mentioned previously, albolabrin and flavoridin, which are structurally more related to each other than to echistatin, appear to be more selective inhibitors of platelet adhesion. Previous studies show that trigramin (which is similar to albolabrin and flavoridin in molecular weight and sequence) binds with a much lower affinity to resting than to activated platelets. 16 On the other hand, the binding affinity of echistatin to platelets is only slightly influenced by platelet activation. At present, it is difficult to explain these differences. However, one possible explanation may be the varying affinities of short compared with medium disintegrins for resting compared with activated platelets. Several relevant points have previously been established by the comparison of trigramin (medium) and echistatin (short). First, short disintegrins have a higher affinity for resting platelets than do medium disintegrins.16"8 Conversely, medium disintegrins have a higher affinity for activated platelets than do short disintegrins.1618 Perhaps echistatin (short) is more an inhibitor of platelet aggregation in the present study, because it has already attached to the resting platelets during recirculation and is, therefore, available to prevent aggregation immediately upon stimulation. On the other hand, medium disintegrins (flavoridin and albolabrin in these experiments) would not be as likely to interact with platelets before stimulation and would, therefore, appear less potent in inhibiting aggregation. However, there would be more of these medium disintegrins available to prevent platelet adhesion to the surfaces of the circuit, because they are less likely to be bound to the circulating resting platelets. Also, the recently described platelet fibronectin receptors (glycoprotein be eliminated from the circulation shortly after the termination of the bypass.
Several previous strategies to preserve platelet numbers and function during cardiopulmonary bypass have proved disappointing or inconclusive. For example, precoating the circuit with albumin preserves platelets in the simulated extracorporeal circuit1136 but not in vivo. Attempts to block the platelet binding sites of surface adsorbed fibrinogen12,37 have not been extended to clinical trials. The use of desmopressin acetate to increase von Willebrand factor during cardiopulmonary bypass reduced postoperative blood loss in one study10; however, infusions of desmopressin seem to carry the risk of thrombosis, particularly in elderly patients and in those with atherosclerosis. 38 The vasodilatory effects of PGE1 and prostacyclin (PGI2) preclude their use as platelet inhibitors during open heart surgery. 39, 40 Iloprost, an experimental drug, is an analogue of prostacyclin and partially inhibits platelets by increasing platelet cyclic AMP.41 It partially protected platelets during simulated extracorporeal circulation,41 during experimental cardiopulmonary bypass in dogs42 and in patients during open heart surgery who had heparin-induced thrombocytopenia. 43 These results support the theory that an antiplatelet agent would be beneficial during surgery requiring cardiopulmonary bypass. However, because iloprost administration results in dangerous hypotension,43 perhaps disintegrins can serve as an appropriate alternate for prostanoids in these circumstances. Also, the use of disintegrins and PGE1 or PGI2 together may be effective, because each inhibits platelets by different mechanisms. This combination therapy may adequately reduce the adverse effects of vasodilatory prostaglandins, because the amount required would be decreased.
In conclusion, we demonstrated the protective effects on platelets in simulated extracorporeal circulation of four disintegrins: echistatin, bitistatin, flavoridin, and albolabrin. Flavoridin and albolabrin appeared to be more selective inhibitors of platelet adhesion to surfaces than of platelet aggregation. Therefore, these substances may be more attractive clinically than is echistatin, because inhibition of platelet aggregation may involve risk of bleeding. At present, the side effects of the disintegrins are not known in detail, but our data indicate that these disintegrins can be infused safely in animals without detrimental effects on blood pressure or core temperature.1921 This new class of peptides does raise the prospect of controlling the excessive blood losses associated with contemporary open heart surgery.
